Stem cell and exosome therapy for lupus in Istanbul, Turkey
Individualized Wharton's jelly MSC and exosome protocols designed to support systemic immune regulation and microvascular homeostasis alongside your ongoing rheumatology care.
Understanding systemic lupus erythematosus and how biologics restore immune and vascular balance
Systemic lupus erythematosus (SLE) is a complex, multi-organ autoimmune condition in which the immune system loses self-tolerance to the body's own cellular nuclei. Hyperactive helper T cells stimulate B lymphocytes to produce autoantibodies—such as anti-dsDNA—which bind to cellular debris and form circulating immune complexes. As these complexes deposit along delicate capillary walls in the kidneys, skin, joints, and serosal membranes, they trigger complement consumption, persistent type-I interferon storms, and microvascular inflammation. For patients, this continuous immune overactivity causes painful joint and skin flares, profound systemic fatigue, and the ongoing threat of lupus nephritis or vascular injury.
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes are studied for their ability to rebalance this dysregulated immune network without wiping out the body's baseline defenses. Administered intravenously and intramuscularly, WJ-MSCs release immunomodulatory mediators—including PGE2, IDO, TGF-beta, and IL-10—that calm autoreactive B-cell maturation, suppress pro-inflammatory Th17 and follicular helper T cells, restore protective regulatory T-cell (Treg) populations, and shift macrophages from inflammatory M1 states toward reparative, debris-clearing M2 phenotypes. Simultaneously, nanoscale WJ-MSC exosomes circulate through stressed renal, cutaneous, and articular capillary beds to deliver anti-inflammatory microRNAs and angiogenic trophic factors (VEGF, HGF) that protect endothelial linings and support tissue repair.
At our Istanbul clinic led by Uzm. Dr. Cihan Bolat, you begin by sharing your rheumatology history, autoimmune panels (ANA, anti-dsDNA, complement C3/C4, CBC), and renal markers. Our medical team designs an individualized IV and intramuscular WJ-MSC and exosome protocol alongside your specialist medications—aimed at quieting flare activity, supporting organ microvasculature, and improving daily stamina and quality of life.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
What happens inside the body in SLE—and how WJ-MSCs and exosomes help repair it
Four interconnected immunologic and vascular processes drive systemic flare activity and organ stress in lupus—each targeted by cellular and vesicular immunomodulation.
Therapeutic objectives of our lupus protocol
Our WJ-MSC and exosome protocols in Istanbul aim to support systemic immune balance and microvascular repair alongside the medications managed by your home rheumatology and nephrology specialists.
Regulating overactive B-cell, T-cell, and dendritic-cell signaling without myeloablative immunosuppression
Expanding protective regulatory T-cell (Treg) populations and shifting macrophages toward reparative M2 states
Calming systemic type-I interferon and pro-inflammatory cytokine cascades linked to flares and chronic fatigue
Protecting and repairing microvascular endothelial linings across renal, cutaneous, and articular tissues
Providing comprehensive pre- and post-treatment laboratory documentation for your home specialist team
01
Loss of self-tolerance & autoreactive B-cell / T-cell signaling
In SLE, overactive helper T cells and elevated B-cell activating factor (BAFF) drive B lymphocytes to differentiate into plasma cells that secrete pathogenic autoantibodies against nuclear antigens such as double-stranded DNA (dsDNA).
Wharton's jelly MSCs and exosomes intervene by secreting IDO, PGE2, and regulatory cytokines that suppress autoreactive T-cell proliferation, downregulate excessive B-cell activation, and help quiet autoantibody-driven flare cascades without ablating host immunity.
Circulating antigen-antibody complexes lodge along the basement membranes of delicate capillaries in the renal glomeruli, skin, and joints, activating the complement cascade (consuming C3 and C4) and injuring vascular endothelial cells.
WJ-MSCs and their exosomes release angiogenic and cytoprotective factors—including VEGF, HGF, and anti-apoptotic microRNAs—that support endothelial barrier repair, calm complement-mediated vascular inflammation, and protect glomerular and dermal microvessels.
03
Persistent type-I interferon & cytokine storms
Plasmacytoid dendritic cells and pro-inflammatory M1 macrophages respond to un-cleared nuclear debris by releasing continuous waves of type-I interferons, TNF-alpha, IL-6, and IL-1beta that cause fever, joint pain, and debilitating chronic fatigue.
By reprogramming macrophages from pro-inflammatory M1 states into reparative, debris-clearing M2 phenotypes and calming dendritic-cell hyperreactivity, WJ-MSCs and exosomes help dampen systemic interferon and cytokine storms.
Patients with active lupus consistently exhibit reduced numbers and impaired function of regulatory T cells (Tregs), leaving target organs unprotected against chronic autoimmune attack and progressive interstitial fibrosis.
Wharton's jelly MSCs and exosomal TGF-beta/IL-10 signaling actively promote the expansion of functional Treg populations while delivering anti-fibrotic trophic support to stressed renal, articular, and cutaneous tissues.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Biological repair rationale
Restoring immune braking pathways and clearing cellular debris
At the core of lupus pathogenesis is a dual defect: macrophages fail to clear normal apoptotic cellular debris efficiently, and depleted regulatory T cells (Tregs) cannot restrain autoreactive B and T lymphocytes from mounting relentless interferon and autoantibody cascades.
Rather than relying solely on broad immunosuppression, biological therapy with WJ-MSCs and exosomes is investigated to restore the immune system's natural regulatory brakes while supporting the endothelial and parenchymal tissues stressed by immune-complex deposition.
Synergistic cellular & vesicular action
Non-myeloablative immune modulation plus microvascular repair
Wharton's jelly MSCs and their purified exosomes work synergistically across lymphoid and organ tissues. Live WJ-MSCs sense systemic interferon and cytokine elevations, dynamically secreting factors that inhibit B-cell activating factor (BAFF) signaling, expand CD4+CD25+FoxP3+ regulatory T cells, and promote efferocytosis (healthy clearance of cellular debris by M2 macrophages).
In parallel, nanoscale WJ-MSC exosomes traverse the microcirculation of the kidneys, skin, and joints to deliver protective microRNAs and trophic proteins that calm endothelial inflammation and oppose fibrotic tissue remodeling.
Individualized clinical planning
Combining IV and intramuscular routes around your organ profile
Because lupus affects every patient differently—ranging from mucocutaneous and articular flares to lupus nephritis or hematologic sensitivity—our medical team tailors every protocol to your specific organ biomarkers and current rheumatology regimen.
Uzm. Dr. Cihan Bolat's team combines systemic intravenous infusions with intramuscular depot administration when prolonged paracrine release is desired, monitoring your labs before and after treatment in Istanbul while you continue your prescribed lupus medications.
Our treatment approach & administration routes
Our lupus biologics and administration routes
Based on your medical evaluation and organ profile, our team structures an individualized protocol combining intravenous and intramuscular Wharton's jelly biologics.
01
Intravenous Wharton's Jelly MSC Infusion
Intravenous infusion of GMP-cultivated Wharton's jelly MSCs introduces live, immunologically privileged stromal cells into the systemic circulation. Responding dynamically to inflammatory cytokines, these cells interact with splenic, lymphatic, and vascular immune populations to inhibit autoreactive lymphocyte proliferation, promote Treg expansion, and secrete trophic factors (HGF, VEGF) that support organ microvasculature.
Role in your protocolDosed precisely according to body weight and organ stability under close clinical and laboratory observation in Istanbul.
02
Intravenous WJ-MSC Exosome Administration
Purified WJ-MSC-derived exosomes circulate unobstructed through the fine capillary beds of the kidneys, skin, joints, and serosal tissues. Their nanoscale lipid-bilayer vesicles deliver immunoregulatory microRNAs, anti-inflammatory proteins, and antioxidant enzymes directly into stressed endothelial, tubular, and immune cells.
Role in your protocolComplements live-cell infusions with rapid, systemic nanoscale vesicular signaling across all affected organ systems.
When MSCs are infused intravenously, a substantial fraction initially lodges in the pulmonary microvasculature (the pulmonary first-pass effect). Adding intramuscular administration places a portion of the biologics into well-perfused muscle tissue, creating a localized depot where cells persist longer outside the lungs and release sustained paracrine immunomodulatory signals into the circulation.
Role in your protocolIncluded in individualized lupus protocols when our medical team recommends extending the window of systemic paracrine immune regulation.
04
Organ-Specific Lab Monitoring & Care Continuity
Every lupus protocol in Istanbul includes structured pre- and post-treatment blood and urine panels—evaluating CBC, serum creatinine, eGFR, CRP, ESR, complement C3/C4, anti-dsDNA context, and urinalysis—to monitor organ safety and early biological responses.
Role in your protocolYou continue your prescribed antimalarials and specialist medications without interruption and receive a complete report for your home rheumatologist.
What we aim to achieve
How we monitor immunologic balance and organ repair support
We combine objective laboratory biomarkers with clinical symptom tracking so you and your home rheumatologist can evaluate how biological immunomodulation translates into organ stability and daily well-being over three, six, and twelve months.
01
Lupus disease activity & flare stability
As WJ-MSCs and exosomes support regulatory T-cell balance and calm pro-inflammatory cytokine cascades, we track validated disease activity indices (such as SLEDAI), reductions in joint swelling and mucocutaneous sensitivity, and longer, more predictable intervals between systemic flares.
Active lupus flares typically consume serum complement proteins (lowering C3 and C4) while elevating anti-dsDNA titers and ESR/CRP. Longitudinal follow-up with your rheumatologist monitors trends toward complement normalization, steadier blood counts, and quieter inflammatory markers.
03
Renal & microvascular protection parameters
For patients with a history of lupus nephritis or microvascular involvement, trophic and anti-fibrotic signaling (HGF, VEGF, exosomal microRNAs) aims to support glomerular endothelial and tubular integrity—tracked through serial serum creatinine, eGFR, urinalysis, and urine protein-to-creatinine ratios.
Persistent type-I interferon activity is a major driver of the deep, unrefreshing exhaustion experienced in SLE. Quieting this systemic inflammatory signaling aims to help restore daytime stamina, cognitive clarity, joint comfort, and overall quality of life.
How treatment is personalized
How our 6-step lupus evaluation works
You begin by sharing your rheumatology history, autoimmune blood panels, and organ records. Our medical team under Uzm. Dr. Cihan Bolat evaluates your clinical stability, designs an individualized IV and intramuscular WJ-MSC and exosome protocol where appropriate, and explains the biologics, therapeutic objectives, and costs before you travel to Istanbul.
Medical history & reports we request
Rheumatology diagnosis summary, disease duration, and history of organ involvement
Autoimmune and laboratory panels: ANA, anti-dsDNA, complement C3/C4, CRP, ESR, and CBC
Renal function labs: serum creatinine, eGFR, urinalysis, and urine protein-to-creatinine or ACR ratio
Complete list of current medications (hydroxychloroquine, immunosuppressants, biologics, corticosteroids)
Relevant organ records (kidney biopsy, echocardiogram, pulmonary, or clotting/antiphospholipid history)
Clinical suitability & timing checks
Active systemic infection, unexplained fever, or severe unassessed cytopenia
Acute, unstable lupus crisis (such as rapidly progressive nephritis, acute CNS vasculitis, or acute myocarditis) requiring inpatient hospital care
Active thrombosis or unstable antiphospholipid anticoagulation status making air travel unsafe
Pregnancy or active malignancy
What the patient journey looks like
From your first inquiry to individualized treatment in Istanbul
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
Lupus stem cell and exosome therapy cost in Istanbul
Once our medical team reviews your rheumatology and organ records, you receive a transparent, itemized written protocol specifying the recommended intravenous WJ-MSCs, intravenous WJ-MSC exosomes, any intramuscular administration, laboratory monitoring, and total cost.
For context, our 2026 systemic Wharton's jelly MSC and exosome programs generally range from $7,000 to $18,000 depending on total biologic dosage, route combination, and number of sessions.
Total intravenous Wharton's jelly MSC count and WJ-MSC exosome concentration
Inclusion of intramuscular biologic administration alongside systemic IV infusions
Number of staged sessions and pre-/post-treatment immunological and renal lab checks in Istanbul
Physician consultations, clinical monitoring, and VIP airport/hotel/clinic transfers
How do Wharton's jelly MSCs and exosomes regulate overactive B and T cells in lupus without wiping out baseline immunity?
02
Why does my protocol combine intravenous infusions with intramuscular administration?
03
How many days will I need to spend in Istanbul for my lupus protocol and lab checks?
04
How will my Istanbul treatment report help my rheumatologist track my complement, anti-dsDNA, and renal markers?
Evidence & important considerations
Published clinical trials in lupus MSC research
Early-phase clinical studies in Europe and the United States evaluate the safety, feasibility, and immunologic signaling of allogeneic umbilical cord and Wharton's jelly MSC infusions in refractory SLE.
WJ-MSCs and WJ-MSC-derived exosomes are studied for modulating overactive T cells, B cells, dendritic cells, and macrophages while encouraging regulatory T-cell (Treg) balance. Unlike myeloablative chemotherapy protocols, MSC and exosome therapy aims to calm pro-inflammatory cytokine signaling without ablating your baseline immune system.
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.
